RT Journal Article SR Electronic T1 Adiponectin/leptin ratio - a marker of insulin sensitivity in pre-eclampsia and fetal growth JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.10.13.22281056 DO 10.1101/2022.10.13.22281056 A1 Victoria Elizabeth de Knegt A1 Paula L. Hedley A1 Anna K. Eltvedt A1 Sophie Placing A1 Karen Wøjdemann A1 Anne-Cathrine Shalmi A1 Line Rode A1 Jørgen Kanters A1 Karin Sundberg A1 Ann Tabor A1 Ulrik Lausten-Thomsen A1 Michael Christiansen YR 2022 UL http://medrxiv.org/content/early/2022/10/17/2022.10.13.22281056.abstract AB The serum adiponectin-leptin ratio (A/L ratio) is a surrogate marker of insulin sensitivity. Pre-eclampsia (PE) is associated with maternal metabolic syndrome and occasionally impaired fetal growth. We assessed whether the A/L ratio in first-trimester maternal serum was associated with PE and/or birth weight. Adiponectin and leptin were quantitated in first-trimester blood samples (gestational week 10+3-13+6) from 126 women who later developed PE with proteinuria, (98 mild PE; 21 severe PE; 7 HELLP syndrome), and 297 controls, recruited from the Copenhagen First-Trimester Screening Study. The A/L ratio was reduced in PE pregnancies, median 0.17 (IQR: 0.12-0.27) compared to controls, median 0.32 (IQR: 0.19-0.62), (p<0.001). A multiple logistic regression showed that PE was negatively associated with A/L ratio independent of maternal BMI (odds ratio = 0.08, 95% CI = 0.0322 to 0.214). Adiponectin (AUC = 0.632) and PAPP-A (AUC = 0.605) were negatively, and leptin (AUC = 0.712) was positively associated with PE. However, the A/L ratio was a better predictor of PE (AUC = 0.737). No significant association was found between A/L ratio and clinical severity of pre-eclampsia or preterm birth. PE was associated with significantly lower relative birth weight, (p<0.001). A significant negative correlation was found between relative birth weight and A/L ratio in controls but not in PE pregnancies, (β = −0.144, 95% CI = −9.944 to −0.093), independent of maternal BMI. After correction for maternal BMI, leptin was significantly associated with relative birth weight, (β = 0.197, 95 % CI = 2.361 to 14.353), while adiponectin was not significantly associated. Our findings suggest that an impairment of the A/L ratio (as seen in metabolic syndrome) in first-trimester is characteristic of PE, while aberrant fetal growth in PE is not dependent on insulin sensitivity but rather on leptin associated pathways.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study as a sub-study of the Copenhagen First Trimester Screening Study, and approved by the Scientific Ethics Committee for Copenhagen and Frederiksberg Counties (No (KF) 01-288/97)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.AGAappropriate-for-gestational-ageA/L ratioserum adiponectin-leptin ratioAUCarea under the curveBMIbody mass indexCRLcrown rump lengthELISAenzyme-linked immunosorbent assayFGRfetal growth restrictionGAgestational ageGDMgestational diabetes mellitusHCGβbeta-chorionic gonadotropinHMWhigh molecular weightIGFinsulin-like growth factorIGFBPinsulin-like growth factor binding proteinIRinsulin resistanceISinsulin sensitivityISSHPThe International Society for the Study of HypertensionLGAlarge-for-gestational-ageMoMmultiple of the medianPAPP-Apregnancy-associated plasma protein APCOSpolycystic ovary syndromePEpre-eclampsiaROCreceiver operating characteristicSGAsmall-for-gestational-age